Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
24-Homo-1,25-dihydroxyvitamin D3 is a synthetic analogue of vitamin D. It is structurally related to calcitriol (the active form of vitamin D), but with a modification at the C24 position ("homo" indicates an additional methylene group). This compound acts as a vitamin D receptor agonist and is being investigated for its potential biological activities similar to those of natural vitamin D metabolites. Its primary mechanism involves binding to and activating the vitamin D receptor (VDR), thereby modulating gene expression involved in calcium and phosphate homeostasis as well as cell differentiation. It remains experimental and has not been approved for clinical use[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 24-Homo-1,25-dihydroxyvitamin D3.